Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

r $168,395, to $2.1 million for the six months ended June 30, 2009, compared to $2.3 million for the same period in 2008. These decreases were primarily due to a decrease in personnel related expenses through personnel reductions, a decrease in travel expenses, and a reduction in insurance premium expense. These decreases were offset by an increase in outside services related to investment banking activities and an increase in legal expenses.

Other income decreased 98%, or $55,774 to $958 for the three months ended June 30, 2009, compared to $56,732 for the comparable period in 2008 and decreased 95%, or $145,137 to $7,600 for the six months ended June 30, 2009, compared to $152,737 for the same period in 2008. These decreases were due to a decrease in interest income due to lower cash balances.

Net loss decreased 26%, or $540,603 to $1.6 million for the three months ended June 30, 2009, compared to $2.1 million for the same period in 2008 and the net loss for the six months ended June 30, 2009, decreased 15%, or $628,477 to $3.5 million, compared with a net loss of $4.1 million for the same period in 2008. These decreases were primarily due to lower operating expenses offset by lower revenues.

Liquidity and Capital Resources

We had approximately $3.1 million in cash and cash equivalents, and $473,711 in restricted cash as of June 30, 2009. Based on our current operating plan, we anticipate that our existing cash and cash equivalents, together with expected royalties from third parties, will fund our operations until late 2009, assuming we do not trigger additional obligations, including contractual severance or lease obligations and unless unforeseen events arise that negatively impact our liquidity. In the event we are unsuccessful generating additional revenues or raising additional funds, we will have to substantially reduce our operations to preserve capital or seek ban
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... The Collaborative R&D Terms and ... comprehensive understanding and unprecedented access to the collaborative ... worlds leading life science companies. , The report ... and why companies enter collaborative R&D deals. , ... deals terms provides critical insight into the negotiation ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 Available ... lighting needs for research and cultivation of a ... by Valoya’s proprietary LEDs with proven patented and ... ensures uncompromised light uniformity in critical applications in ... white LEDs. , “Our customers have a large ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 This ... current state of the Epoxy Hardener industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
Breaking Biology Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... utilizing targeted direct-mail marketing, Middleton-based Customer Potential ... health care provider unexpected returns: Forty-six patients for ... and $152,944 net profit. CPM is a provider ... ,With advancements in variable digital imaging and predictive ...
... Inc. , a Madison-based provider of managed Internet network ... funding from First Analysis , Argentum Group ... will be used to expand the companys sales and ... ,The demand for managed network security is growing dramatically ...
... in the air and we are emerging into the second week ... and say whether this will be a good or bad year ... significant activities have already taken place that impact the land of ... the last two weeks has approved not one but two new ...
Cached Biology Technology:Biotech 2004: Cautious optimism 2Biotech 2004: Cautious optimism 3
(Date:9/2/2014)... contain essentially the same DNA sequence their genetic ... of cells in the different parts of the body ... same construction master plan, an additional regulatory layer exists ... are active. This mechanism involves modifications of genome-bound histone ... (e.g. methylation). It acts on top of the genetic ...
(Date:9/2/2014)... in the September issue of The FASEB ... strategy to diagnose the leading cause of blindness ... has occurred. This advance involves quantifying the early ... of retinal vessels. Using new probes developed by ... molecular development of diabetic retinopathy. , "My goal ...
(Date:9/2/2014)... 2014 A study published in the September ... American Academy of Child and Adolescent Psychiatry ... psychiatric diagnosis had an increased risk of developing ... Using data from the nationwide Danish registers, a ... Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied 48,299children ...
Breaking Biology News(10 mins):Throwing a loop to silence gene expression 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2Risk of diabetes in children and adolescents exposed to antipsychotics 2
... Engineers like to make things that work. And if ... size of proteins, antibodies, and virusesmimicking the behavior of ... carry an enormous amount of information in a very ... computation and neutral systems, and bioengineering, explains, "I tend ...
... DURHAM, N.H. New research from Plymouth State University ... and bleeding horseshoe crabs for biomedical purposes causes short-term ... the crabs, population decline in parts of the east ... harvests the blue blood from almost half a million ...
... from natural disasters usually means rebuilding infrastructure and reassembling ... heal, too, and scientists are pioneering new methods to ... epicenter of China,s devastating Wenchuan earthquake in 2008 was ... biodiversity hotspot and home to the beloved and endangered ...
Cached Biology News:Building artificial cells will be a noisy business 2Building artificial cells will be a noisy business 3Biomedical bleeding affects horseshoe crab behavior 2Biomedical bleeding affects horseshoe crab behavior 3Gauging what it takes to heal a disaster-ravaged forest 2
...
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
... The FDSS6000 System is an ... assays, assay development and high throughput ... and luminescence modalities., The Hamamatsu light ... highlight our companys decades-long experience in ...
... Experion StdSens reagents and supplies, ... and supplies sufficient to perform standard-sensitivity ... chips on the Experion automated electrophoresis ... gel, 20 microliters RNA StdSens stain, ...
Biology Products: